Santa Marta Hospital, Lisbon, Portugal.
Eur Heart J Acute Cardiovasc Care. 2013 Mar;2(1):44-52. doi: 10.1177/2048872612474921.
Serum uric acid (UA) has been shown to be an independent predictor of outcome in the general population and in patients with heart failure. There are, however, limited data regarding the prognostic value of UA in the context of acute coronary syndromes (ACS) particularly in medium-term follow up and the available results are contradictory.
Study of consecutive patients admitted with an ACS (with and without ST-segment elevation) at a single-centre coronary care unit. Primary endpoint was all-cause mortality at 1-year follow up. We evaluated if serum UA is an independent predictor of outcome and if it has any added value on top of GRACE risk score for risk prediction.
We included 683 patients, mean age 64±13 years, 69% males. In-hospital and 1-year mortality were 4.5 and 7.6% respectively. The best cut-off of UA to predict 1-year mortality was 6.25 mg/dl (sensitivity 59%, specificity 72%) and 30.2% of the patients had an increased UA according to this cut off. Independent predictors of UA were male gender (β= 0.078), body mass index (β=0.163), diuretics before admission (β=0.142), and admission serum creatinine (β=0.403). One-year mortality was significantly higher in patients with increased UA (15.5 vs. 4.2%, p<0.001; log rank, p<0.001). After adjustment, both increased UA as a categorical variable (HR 2.25, 95% CI 1.23-4.13, p=0.008) and as a continuous variable (HR 1.26, 95% CI 1.13-1.41, p<0.001) are independent predictors of mortality. The AUC increases only slightly after inclusion of UA in the model with GRACE risk score (from 0.78 to 0.79, p=0.350). Both models had a good fit; however, model fit worsened after inclusion of UA. Overall, the inclusion of UA in the original was associated with an improvement in both the net reclassification improvement (continuous NRI=44%), and the integrated discrimination improvement (IDI=0.052) suggesting effective reclassification.
Serum UA is an independent predictor of all-cause mortality in medium-term after the whole spectrum of ACS and has an added value for risk stratification.
血清尿酸(UA)已被证明是一般人群和心力衰竭患者预后的独立预测因素。然而,关于 UA 在急性冠状动脉综合征(ACS)背景下的预后价值的数据有限,特别是在中期随访中,并且可用的结果存在矛盾。
研究了在单中心冠心病监护病房因 ACS(伴或不伴 ST 段抬高)入院的连续患者。主要终点是 1 年随访时的全因死亡率。我们评估了血清 UA 是否是预后的独立预测因素,以及它是否在 GRACE 风险评分之上对风险预测有额外的价值。
我们纳入了 683 名患者,平均年龄 64±13 岁,69%为男性。住院期间和 1 年死亡率分别为 4.5%和 7.6%。预测 1 年死亡率的最佳 UA 截断值为 6.25mg/dl(敏感性 59%,特异性 72%),根据该截断值,30.2%的患者 UA 升高。UA 的独立预测因素为男性(β=0.078)、体重指数(β=0.163)、入院前利尿剂(β=0.142)和入院时血清肌酐(β=0.403)。UA 升高的患者 1 年死亡率显著升高(15.5%比 4.2%,p<0.001;对数秩检验,p<0.001)。调整后,UA 作为分类变量(HR 2.25,95%CI 1.23-4.13,p=0.008)和连续变量(HR 1.26,95%CI 1.13-1.41,p<0.001)均为死亡率的独立预测因素。在将 UA 纳入 GRACE 风险评分模型后,AUC 仅略有增加(从 0.78 增加到 0.79,p=0.350)。两个模型拟合度都很好,但是加入 UA 后模型拟合度变差。总的来说,在原始模型中加入 UA 后,净重新分类改善(连续 NRI=44%)和综合判别改善(IDI=0.052)均有改善,提示有效的重新分类。
UA 是 ACS 全谱后中期全因死亡率的独立预测因素,对风险分层具有附加价值。